The Journal of Organic Chemistry
Article
CDCl3) δ 162.5, 140.4 (q, J = 1.3 Hz), 139.8, 137.3, 130.0 (q, J = 32.4
Hz), 128.1, 125.7 (q, J = 3.8 Hz), 123.9 (q, J = 274 Hz), 121.3, 106.6,
51.7; IR (neat) 3065, 2917, 1665, 1586, 1536, 1325, 1108 cm−1;
HRMS (ESI-TOF) m/z 276.0608 [276.0612 calcd for C13H10F3NONa
(M + Na)+].
6u30 (331 mg, 1.63 mmol) was treated with LiI (109 mg, 0.81 mmol)
for 26 h. Purification by column chromatography (SiO2, ethyl acetate)
afforded 270 mg (81% yield) of 7u as a yellow oil: H NMR (400
1
MHz, CDCl3) δ 7.70 (dd, J = 2.1, 6.9 Hz, 1H), 7.32 (ddd, J = 2.1, 6.6,
9.0 Hz, 1H), 6.55 (app d, J = 9.2 Hz, 1H), 6.21 (dt, J = 1.4, 6.8 Hz,
1H), 4.72 (t, J = 2.3 Hz, 2H), 2.23 (tt, J = 2.3, 7.2 Hz, 2H), 1.53
(pentet, J = 7.2 Hz, 2H), 1.26−1.40 (m, 4H), 0.89 (t, J = 7.1 Hz, 3H);
13C NMR (100 MHz, CDCl3) δ 162.4, 139.7, 136.0, 120.6, 106.1, 88.8,
73.0, 38.4, 31.3, 28.3, 22.4, 19.1, 14.2; IR (neat) 3458, 3078, 2932,
2856, 2228, 1659, 1588, 1534, 1462, 1350, 1259, 1142 cm−1; HRMS
(ESI-TOF) m/z 204.1390 [204.1388 calcd for C13H18NO (M + H)+].
5-Phenyl-1-(2-pyridonyl)pent-2-yne (7v). Following the gen-
eral procedure above for the preparation of compound 7f, 2-
propargyloxypyridine 6v30 (156 mg, 0.66 mmol) was treated with
LiI (65 mg, 0.48 mmol) for 26 h. Purification by column
chromatography (SiO2, 1:1 hexane/ethyl acetate) afforded 133 mg
(85% yield) of 7v as a brown oil: 1H NMR (400 MHz, CDCl3) δ 7.49
(dd, J = 2.1, 6.9 Hz, 1H), 7.19−7.35 (m, 6H), 6.54 (dt, J = 0.6, 9.2 Hz,
1H), 6.14 (app t, J = 6.6 Hz, 1H), 4.69 (t, J = 2.2 Hz, 2H), 2.85 (t, J =
7.4 Hz, 2H), 2.57 (tt, J = 2.4, 7.4 Hz, 2H); 13C NMR (100 MHz,
CDCl3) δ 162.2, 140.2, 139.7, 135.9, 128.4, 126.3, 120.2, 106.2, 105.9,
87.6, 73.7, 38.2, 34.6, 20.8; IR (neat) 3028, 2928, 2235, 1667, 1651,
1538, 1454, 1353, 1261, 1145 cm−1; HRMS (ESI-TOF) m/z 260.1044
[260.1051 calcd for C16H15NONa (M + Na)+].
(N)-(4-Cyanomethylbenzyloxy)-2-pyridone (7g). Following
the general procedure above for the preparation of compound 7f, 2-
(4-cyanomethylbenzyloxy)pyridine (6g, 174 mg, 0.83 mmol) was
treated with LiI (55 mg, 0.41 mmol) for 26 h. Purification by column
chromatography (SiO2,1:1 hexanes/ethyl acetate) afforded 104 mg
1
(60%) of 7g as a white solid: mp 136−137 °C; H NMR (400 MHz,
CDCl3) δ 7.56 (d, J = 8.2 Hz, 2H), 7.28−7.36 (m, 3H), 7.24 (dd, J =
0.9, 6.7 Hz, 1H), 6.56 (d, J = 9.2 Hz, 1H), 6.16 (t, J = 6.7 Hz, 1H),
5.13 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 162.4, 141.7, 139.9,
137.2, 132.6, 128.3, 121.4, 118.5, 111.7, 106.7, 51.9; IR (neat) 3433,
3065, 2228, 1659, 1585, 1538 cm−1; HRMS (ESI-TOF) m/z 233.0699
[233.0691 calcd for C13H10N2ONa (M + Na)+].
(N)-Benzyloxy-6-methyl-2-pyridone (7r). Following the general
procedure above for the preparation of compound 7f, 2-benzyloxy-6-
methylpyridine (6r, 108 mg, 0.54 mmol) was treated with LiI (36 mg,
0.27 mmol) for 26 h. Purification by column chromatography
(SiO2,1:1 hexanes/ethyl acetate) afforded 65 mg (60%) of 7r as a
1
white solid: mp 103−105 °C; H NMR (400 MHz, CDCl3) δ 7.18−
7.31 (m, 4H), 7.12 (d, J = 7.1 Hz, 2H), 6.52 (d, J = 9.0 Hz, 1H), 6.00
(d, J = 6.9 Hz, 1H), 5.33 (s, 2H), 2.24 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 163.9, 146.6, 139.1, 136.4, 128.8, 127.3, 126.4, 117.8, 107.0,
47.1, 20.6; IR (neat) 3448, 3033, 2962, 1656, 1550, 1407, 1144 cm−1;
HRMS (ESI-TOF) m/z 222.0888 [222.0895 calcd for C13H13NONa
(M + Na)+].
1-Cyclohexyl-3-(2-pyridonyl)prop-1-yne (7w). Following the
general procedure above for the preparation of compound 7f, 2-
propargyloxypyridine 6w30 (149 mg, 0.69 mmol) was treated with LiI
(110 mg, 0.82 mmol) for 26 h. Purification by column chromatog-
raphy (SiO2, 1:1 hexane/ethyl acetate) afforded 114 mg (77% yield) of
1
(N)-Benzyl-6-benzyloxy-1-pyridazone (9) and (N,N)-Diben-
zyl-1,4-pyridazone (10). Following the general procedure above for
the preparation of compound 7f, 3,6-dibenzyloxypyridazine (8,21 104
mg, 0.39 mmol) was treated with LiI (27 mg, 0.20 mmol) for 26 h.
Purification by column chromatography (SiO2, 1:1 hexanes/ethyl
acetate) afforded 66 mg (63%) of 9 and 6 mg (6%) of 10. Compound
7w as a brown oil: H NMR (400 MHz, CDCl3) δ 7.73 (dd, J = 2.2,
7.0 Hz, 1H), 7.33 (ddd, J = 1.6, 8.6, 10.8 Hz, 1H), 6.56 (d, J = 9.1 Hz,
1H), 6.22 (t, J = 6.8 Hz, 1H), 4.74 (d, J = 2.0 Hz, 2H), 2.38−2.46 (m,
1H), 1.77−1.87 (m, 2H), 1.68−1.73 (m, 2H), 1.40−1.54 (m, 3H),
1.25−1.36 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 162.2, 139.4,
135.6, 120.3, 105.9, 92.7, 72.6, 38.1, 32.4, 29.1, 25.7, 24.8; IR (neat)
2930, 2855, 2235, 1668, 1574, 1538, 1449, 1351, 1258, 1144 cm−1;
HRMS (ESI-TOF) m/z 238.1203 [238.1208 calcd for C14H17NONa
(M + Na)+].
1-Phenyl-3-(2-pyridonyl)prop-1-yne (7x). Following the gen-
eral procedure above for the preparation of compound 7f, 2-
propargyloxypyridine 6x30 (102 mg, 0.49 mmol) was added to LiI
(130 mg, 0.97 mmol) for 26 h. Purification by column chromatog-
raphy (SiO2, 1:1 hexane/ethyl acetate) afforded 67 mg (77% yield) of
7x as a yellow oil: 1H NMR (400 MHz, CDCl3) δ 7.75 (dd, J = 1.8, 6.9
Hz, 1H), 7.48 (app dd, J = 1.6, 7.4 Hz, 2H), 7.40−7.27 (m, 4H), 6.61
(d, J = 9.2 Hz, 1H), 6.27 (dt, J = 1.3, 6.8 Hz, 1H), 5.00 (s, 2H); 13C
NMR (100 MHz, CDCl3) δ 162.4, 139.9, 136.1, 132.1, 129.1, 128.6,
122.2, 120.8, 106.5, 87.4, 82.2, 38.7; IR (neat) 3072, 3030, 2970, 2235,
1660, 1587, 1538, 1490, 1352, 1146 cm−1; HRMS (ESI-TOF) m/z
232.0731 [232.0738 calcd for C14H11NONa (M + Na)+].
1-((5-Methyl)-2-pyridonyl)oct-2-yne (7z). Following the general
procedure above for the preparation of compound 7f, 2-propargylox-
ypyridine 6z30 (120 mg, 0.55 mmol) was treated with LiI (74 mg, 0.55
mmol) for 26 h. Purification by column chromatography (SiO2, 1:1
hexane/ethyl acetate) afforded 76 mg (64% yield) of 7z as a yellow oil:
1H NMR (400 MHz, CDCl3) δ 7.41 (broad s, 1H), 7.16 (dd, J = 2.2,
9.3 Hz, 1H), 6.47 (d, J = 9.1 Hz, 1H), 4.67 (s, 2H), 2.21 (app t, J = 7.1
Hz, 2H), 2.08 (s, 3H), 1.51 (pentet, J = 7.0 Hz, 2H), 1.24−1.39 (m,
4H), 0.88 (app t, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ
158.8, 139.6, 130.7, 117.4, 112.4, 85.4, 70.6, 35.4, 28.5, 25.6, 19.6, 16.2,
14.7, 11.4; IR (neat) 2952, 2929, 2861, 2254, 2230, 1673, 1596, 1532,
1461, 1259, 1142 cm−1; HRMS (ESI-TOF) m/z 218.1546 [218.1545
calcd for C14H20NO (M + H)+].
1
9: mp 83−84 °C; H NMR (400 MHz, CDCl3) δ 7.22−7.38 (m,
10H), 6.86−6.93 (m, 2H), 5.17 (s, 2H), 5.13 (s, 2H); 13C NMR (100
MHz, CDCl3) δ 158.8, 152.1, 136.4, 135.9, 133.1, 128.7, 128.51,
128.48, 128.3, 128.2, 127.7, 126.5, 68.8, 54.4; IR (neat) 3448, 3033,
2947, 1668, 1590, 1438, 1279 cm−1; HRMS (ESI-TOF) m/z 315.1102
1
[315.1110 calcd for C18H16N2O2Na (M + Na)+]. Compound 10: H
NMR (400 MHz, CDCl3) δ 7.20−7.35 (m, 6H), 7.02 (d, J = 7.3 Hz,
4H), 6.99 (s, 2H), 5.08 (s, 4H); 13C NMR (100 MHz, CDCl3) δ
157.4, 134.9, 134.7, 129.2, 128.2, 126.1, 48.2; IR (neat) 3484, 3033,
2924, 1641, 1595, 1455, 1285, 1136 cm−1; HRMS (ESI-TOF) m/z
315.1110 [315.1110 calcd for C18H16N2O2Na (M + Na)+].
5-Phenyl-1-(2-pyridonyl)pent-2-ene (7t). Following the general
procedure above for the preparation of compound 7f, (E)-2-(5-phenyl-
2-pentenyloxy)pyridine (E-6t, 354 mg, 1.48 mmol) was treated with
LiI (99 mg, 0.74 mmol) for 26 h. Purification by column
chromatography (SiO2, ethyl acetate) afforded 207 mg (58%) of E-
7t and 101 mg (29%) of Z-7t as viscous orange oils.44 Compound E-
7t: 1H NMR (400 MHz, CDCl3) δ 7.09−7.32 (m, 7H), 6.56 (ddd, J =
0.7, 1.3, 9.1 Hz, 1H), 6.11 (td, J = 1.4, 6.7 Hz, 1H), 5.67−5.76 (m,
1H), 5.52−5.61 (m, 1H), 4.48 (dd, J = 1.0, 6.3 Hz, 2H), 2.71 (t, J = 7.6
Hz, 2H), 2.39 (app q, J = 7.3 Hz, 2H); 13C NMR (100 MHz, CDCl3)
δ 162.7, 141.6, 139.5, 137.0, 135.2, 128.7, 128.6, 126.1, 125.2, 121.1,
106.2, 50.4, 35.5, 34.1; IR (neat) 3468, 3026, 2927, 1656, 1588, 1538,
1144 cm−1; HRMS (ESI-TOF) m/z 262.1201 [262.1208 calcd for
1
C16H17NONa (M + Na)+]. Compound Z-7t: H NMR (400 MHz,
CDCl3) δ 7.17−7.32 (m, 6H), 6.81 (ddd, J = 0.7, 2.1, 6.8 Hz, 1H),
6.52 (ddd, J = 0.6, 1.4, 9.2 Hz, 1H), 6.03 (td, J = 1.4, 6.7 Hz, 1H),
5.69−5.77 (m, 1H), 5.43−5.51 (m, 1H), 4.48 (dd, J = 1.6, 7.0 Hz,
2H), 2.74 (t, J = 7.3 Hz, 2H), 2.52 (app q, J = 7.3 Hz, 2H); 13C NMR
(100 MHz, CDCl3) δ 162.8, 141.5, 139.4, 136.9, 134.1, 128.9, 128.7,
126.3, 124.8, 121.0, 106.2, 45.3, 35.7, 29.6; IR (neat) 3468, 3026, 2927,
1656, 1588, 1538, 1144 cm−1; HRMS (ESI-TOF) m/z 262.1201
[262.1208 calcd for C16H17NONa (M + Na)+].
3-Iodo-4-triisopropylsiloxy-2-(2-pyridonyl)but-2-en-1-ol
(22bb). LiI (45 mg, 0.33 mmol) was added to 2-propargyloxypyridine
6bb30 (107 mg, 0.33 mmol) in a 1 dram screw-top vial, and the
reaction was warmed to 100 °C for 26 h. Purification of the residue by
column chromatography (SiO2, 1:1 hexane/ethyl acetate) afforded 24
1
1-(2-Pyridonyl)oct-2-yne (7u). Following the general procedure
above for the preparation of compound 7f, 2-propargyloxypyridine
mg (16% yield) of 22bb as a white powder: mp 93−95 °C, H NMR
(400 MHz, CDCl3) δ 7.38 (t, J = 8.0 Hz, 1H), 7.17 (d, J = 6.4 Hz,
I
dx.doi.org/10.1021/jo3015424 | J. Org. Chem. XXXX, XXX, XXX−XXX